American Well Corporation AMWL PHARMA
Company Overview
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint, a device enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings; Amwell Converge, a platform and wraparound services of digital care into the in-person, automated, and virtual care settings; and Behavioral Health, a platform that offer students and faculty the right level of care. It also provides specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care for patients and members; Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. It serves providers, payers, and the government, as well as the higher education sector. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Revenue has grown at a 11.8% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $249.32M (-2.0% YoY); net profit $-95.70M.
- Trailing 12 Months Year-on-year growth — revenue -26.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.83% |
| 1 Year: | -26.60% |
Stock Price Performance
| 1 Year: | +85.54% |
| 6 Months: | +139.93% |
| 3 Months: | +52.46% |
| 1 Month: | -1.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.26 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMWL American Well Corporation PHARMA | 13.34 | -2.79 | $200.92M | 0.00% | -42.01% | -29.12% | 11.83% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 53.71M | 68.57M | 62.55M | 57.60M | 60.22M | 62.22M | 64.23M | 64.52M | 69.21M | 64.00M | 62.45M | 61.92M | 59.52M | 62.79M | 61.05M | 66.83M | 70.90M | 56.29M | 54.88M | 52.05M |
| Operating Income | -25.75M | -25.75M | -87.83M | -64.29M | -38.74M | -37.53M | -55.45M | -70.48M | -69.40M | -71.12M | -397.32M | -94.51M | -143.36M | -75.03M | -52.38M | -47.37M | -30.41M | -20.38M | -29.33M | -17.42M | -9.56M |
| Net Income | -24.02M | -24.38M | -86.66M | -63.08M | -39.19M | -37.86M | -51.49M | -70.04M | -69.14M | -70.08M | -397.69M | -92.47M | -136.41M | -72.11M | -49.92M | -43.46M | -18.70M | -19.70M | -32.38M | -10.89M | -9.93M |
| Diluted EPS | - | - | - | - | - | -0.15 | -0.20 | -0.26 | -0.25 | -0.25 | -1.42 | -6.53 | -9.54 | -4.94 | -3.36 | -2.87 | -1.19 | -1.24 | -2.00 | -0.66 | -0.59 |
| R&D Expense | 13.60M | 14.94M | 17.64M | 25.27M | 23.04M | 22.38M | 27.40M | 37.48M | 37.07M | 36.25M | 25.92M | 25.84M | 27.71M | 26.68M | 20.81M | 19.80M | 22.10M | 18.24M | 18.58M | 12.38M | 10.35M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 113.95M | 148.86M | 245.26M | 252.79M | 277.19M | 259.05M | 254.36M | 249.32M |
| Operating Income | -55.11M | -94.70M | -227.43M | -179.15M | -275.85M | -692.14M | -217.53M | -105.27M |
| Net Income | -52.67M | -87.19M | -224.43M | -176.33M | -270.43M | -675.16M | -208.14M | -95.70M |
| Diluted EPS | - | - | -2.27 | -0.69 | -19.72 | -47.50 | -13.88 | -5.96 |
| R&D Expense | 36.27M | 53.94M | 84.41M | 106.59M | 138.49M | 105.83M | 86.06M | 72.86M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 499.88M | 1.38B | 1.45B | 1.22B | 589.71M | 435.97M | 323.79M |
| Total Equity | -161.75M | -204.41M | -307.12M | 1.22B | 1.24B | 1.06B | 464.22M | 304.77M | 235.58M |
| Cash & Equivalents | - | 47.98M | 137.67M | 941.62M | 746.42M | 538.55M | 372.04M | 228.32M | 182.33M |
| Total Liabilities | - | - | 124.95M | 130.45M | 184.96M | 133.71M | 109.52M | 119.72M | 76.00M |
| Current Liabilities | - | - | 106.58M | 120.98M | 141.63M | 114.06M | 93.80M | 111.26M | 73.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -74.01M | -81.89M | -112.46M | - | -192.32M | -148.34M | -127.34M | -65.95M |
| Investing Cash Flow | -245.93M | 120.00M | -66.76M | - | -11.63M | -19.17M | -18.65M | 17.10M |
| Financing Cash Flow | 278.18M | 46.64M | 983.12M | - | -3.61M | 2.15M | 1.38M | 840.00K |
| Capital Expenditure | -1.91M | -1.34M | -3.32M | - | -10.45M | -15.25M | -15.22M | -21.00K |
| Free Cash Flow | -75.92M | -83.23M | -115.78M | - | -202.77M | -163.59M | -142.56M | -65.97M |
| Net Change in Cash | - | - | - | - | -207.56M | -165.36M | -144.61M | -48.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | -48.4% | -63.6% | -92.7% | -70.9% | -99.5% | -267.2% | -85.5% | -42.2% |
| Net Margin % | -46.2% | -58.6% | -91.5% | -69.8% | -97.6% | -260.6% | -81.8% | -38.4% |
| ROE % | 25.8% | 28.4% | -18.3% | -14.2% | -25.4% | -145.4% | -68.3% | -40.6% |
| ROCE % | - | -24.1% | -18.1% | -13.7% | -25.0% | -139.6% | -67.0% | -42.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Senvest Management LLC | 8.82% | 1.33M | $18.27M |
| 2 | Morgan Stanley | 8.49% | 1.28M | $17.58M |
| 3 | Cable Car Capital, LP | 6.66% | 1.00M | $13.79M |
| 4 | Vanguard Capital Management LLC | 4.06% | 611.26K | $8.40M |
| 5 | Acadian Asset Management. LLC | 3.28% | 494.44K | $6.80M |
| 6 | Blackrock Inc. | 2.84% | 427.58K | $5.88M |
| 7 | Renaissance Technologies, LLC | 1.75% | 263.22K | $3.62M |
| 8 | Russell Investments Group, Ltd. | 1.21% | 182.24K | $2.51M |
| 9 | Geode Capital Management, LLC | 1.05% | 158.62K | $2.18M |
| 10 | Two Sigma Investments, LP | 0.96% | 145.10K | $2.00M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMWL
American Well (AMWL) Stock Sees Fair Value Lift After Higher Analyst Targets
American Well is back in focus after analysts lifted fair value estimates from US$8.9 to US$12.8, which points to a higher price target range for the stock. The shift reflects recent research that strikes a more constructive tone, with high…
Amwell® receives Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for addressing healthcare fragmentation
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of technology enabled care, has received Frost & Sullivan's 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care P…
Amwell® to participate in upcoming investor conferences
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of technology enabled care, today announced that members of the Amwell management team will participate in the following upcoming investor conferences: Well…
American Well (AMWL) Q2 2026 Earnings Call Transcript
Losses narrowed 53% as subscriptions grew and costs fell 38% year over year.
American Well Corp (AMWL) (Q2 2026) Earnings Call Highlights: Narrows Losses, Secures Key DHA ...
American Well Corp (AMWL) reports improved EBITDA and a major government contract win despite a year-over-year revenue decline.
American Well Q2 Earnings Call Highlights
American Well (NYSE:AMWL), which operates as Amwell, reported second-quarter 2026 revenue of $52 million, down 26.6% from a year earlier, while narrowing its adjusted EBITDA loss and raising its full-year profitability outlook as the compan…
AMWL — Frequently Asked Questions
What is the current share price of American Well Corporation (AMWL)?
As of 2026-09-19 21:16 PDT, American Well Corporation (AMWL) trades at $13.34 on NYSE. Its 52-week range is $3.78 to $13.58.
What is the market capitalisation of AMWL?
American Well Corporation (AMWL) has a market capitalisation of $200.92M on NYSE.
What is the P/E ratio of AMWL?
AMWL trades at a trailing price-to-earnings (P/E) ratio of -2.79. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.94.
What is the return on equity (ROE) of AMWL?
AMWL has a return on equity (ROE) of -29.12%. Its return on capital employed (ROCE) is -42.01%.
Is AMWL a good stock to buy?
This page provides a data-driven analysis of American Well Corporation (AMWL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.